Skip to main content
Top
Published in: Journal of Infection and Chemotherapy 6/2011

01-12-2011 | Original Article

A retrospective study of health care-associated pneumonia patients at Aichi Medical University hospital

Authors: Yuka Yamagishi, Hiroshige Mikamo

Published in: Journal of Infection and Chemotherapy | Issue 6/2011

Login to get access

Abstract

Health care-associated pneumonia (HCAP) was defined in the American Thoracic Society/Infectious Disease Society of America guidelines on hospital-acquired pneumonia in 2005. However, little is known about the occurrence of HCAP in Japan. A retrospective review of background characteristics, pathological conditions, causative organisms, initial treatments, and risk factors for HCAP was conducted to determine the relationship of HCAP to community-acquired pneumonia and hospital-acquired pneumonia. Thirty-five patients who were admitted to our hospital for pneumonia acquired outside our hospital were included and were stratified by disease severity according to the Japanese Respiratory Society risk stratification guidelines (A-DROP [age, dehydration, respiratory failure, orientation disturbance, and shock blood pressure] criteria). All patients had an underlying disease. A total of 70 microbial strains (25 gram-positive, 37 gram-negative, 6 anaerobic, and 2 causative of atypical pneumonia) were isolated from sputum cultures, showing high isolation frequencies of Pseudomonas aeruginosa and Staphylococcus aureus and extremely low isolation frequencies of Streptococcus pneumoniae and Haemophilus influenzae. “History of hospitalization within 90 days before the onset of pneumonia” was the most common risk factor, and most of the patients had two or three risk factors. Initially, monotherapy [mainly tazobactam/piperacillin (TAZ/PIPC), sulbactam/ampicillin (SBT/ABPC), ceftriaxone (CTRX), cefepime (CPFM), carbapenems, or fluoroquinolones] or combination therapy (beta-lactam and fluoroquinolone) were administered and gave clinical effects in 63% (22/35) of cases. Bacteriological effects were seen in most strains (57%; 40/70). Since the causative organisms of HCAP were closely related to those of hospital-acquired pneumonia and not to community-acquired pneumonia, we believe that aggressive chemotherapy using broad-spectrum antimicrobials is needed in the initial treatment.
Literature
1.
go back to reference Ishida T. Etiology of respiratory infections. Antibiot Chemother. 2000;16:1023–8. Ishida T. Etiology of respiratory infections. Antibiot Chemother. 2000;16:1023–8.
2.
go back to reference American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med. 1995;153:1711–25. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med. 1995;153:1711–25.
3.
go back to reference American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.
4.
go back to reference Miyashita N, Matsushima T, Oka M, Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45:419–28.PubMedCrossRef Miyashita N, Matsushima T, Oka M, Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45:419–28.PubMedCrossRef
5.
go back to reference Seki M, Watanabe A, Mikasa K, Kadota J, Kohno S. Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society guidelines. Respirology. 2008;13:880–5.PubMedCrossRef Seki M, Watanabe A, Mikasa K, Kadota J, Kohno S. Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society guidelines. Respirology. 2008;13:880–5.PubMedCrossRef
6.
go back to reference American Thorac Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.CrossRef American Thorac Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.CrossRef
7.
go back to reference Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854–62.PubMedCrossRef Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854–62.PubMedCrossRef
8.
go back to reference Shindo Y, Sato S, Murayama E, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009;135:633–40.PubMedCrossRef Shindo Y, Sato S, Murayama E, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009;135:633–40.PubMedCrossRef
9.
go back to reference Carratal J, Fernndez-Sab N, Ortega L, Castellsagu X, Rosn B, Dorca J, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med. 2005;142(3):165–72. Carratal J, Fernndez-Sab N, Ortega L, Castellsagu X, Rosn B, Dorca J, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med. 2005;142(3):165–72.
10.
go back to reference The Committee for the Japanese Respiratory Society Guidelines for the Management of Respiratory Infections. The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults. Respirology. 2006;11(Suppl 3):S1–133. The Committee for the Japanese Respiratory Society Guidelines for the Management of Respiratory Infections. The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults. Respirology. 2006;11(Suppl 3):S1–133.
11.
go back to reference Niederman MS. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definition and challenges in trial design. Clin Infect Dis. 2010;51(S1):S12–7.PubMedCrossRef Niederman MS. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definition and challenges in trial design. Clin Infect Dis. 2010;51(S1):S12–7.PubMedCrossRef
12.
go back to reference Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumionia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568–73.PubMedCrossRef Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumionia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568–73.PubMedCrossRef
13.
go back to reference Ishida T, Hashimoto T, Arita M, et al. Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. Chest. 1998;114:1588–93.PubMedCrossRef Ishida T, Hashimoto T, Arita M, et al. Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. Chest. 1998;114:1588–93.PubMedCrossRef
14.
go back to reference Miyashita N, Ouchi K, Kawasaki K, et al. Comparison of serological tests for detection of immunoglobulin M antibodies to Chlamydophila pneumoniae. Respirology. 2008;13:427–31.PubMedCrossRef Miyashita N, Ouchi K, Kawasaki K, et al. Comparison of serological tests for detection of immunoglobulin M antibodies to Chlamydophila pneumoniae. Respirology. 2008;13:427–31.PubMedCrossRef
15.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement M100-S20. Wayne: CLSI; 2010. National Committee for Clinical Laboratory Standards, 2004. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement M100-S20. Wayne: CLSI; 2010. National Committee for Clinical Laboratory Standards, 2004.
16.
go back to reference Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 7th ed. CLSI document M11-A7. Wayne: Clinical and Laboratory Standards Institute; 2007. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 7th ed. CLSI document M11-A7. Wayne: Clinical and Laboratory Standards Institute; 2007.
17.
go back to reference Carratalà J, Garcia-Vidal C. What is healthcare-associated pneumonia and how is it managed? Curr Opin Infect Dis. 2008;21:168–73.PubMedCrossRef Carratalà J, Garcia-Vidal C. What is healthcare-associated pneumonia and how is it managed? Curr Opin Infect Dis. 2008;21:168–73.PubMedCrossRef
18.
go back to reference Carratalà J, Mykietiuk A, Fernàndez-Sabé N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007;167:1393–9.PubMedCrossRef Carratalà J, Mykietiuk A, Fernàndez-Sabé N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007;167:1393–9.PubMedCrossRef
19.
go back to reference Venditti M, Falcone M, Corrao S, Licata G, Serra P, The Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150:19–26.PubMed Venditti M, Falcone M, Corrao S, Licata G, Serra P, The Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150:19–26.PubMed
20.
go back to reference Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with health-care associated pneumonia: a single-center experience. Chest. 2008;134:963–8.PubMedCrossRef Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with health-care associated pneumonia: a single-center experience. Chest. 2008;134:963–8.PubMedCrossRef
21.
go back to reference Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis. 2009;22:316–25.PubMedCrossRef Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis. 2009;22:316–25.PubMedCrossRef
Metadata
Title
A retrospective study of health care-associated pneumonia patients at Aichi Medical University hospital
Authors
Yuka Yamagishi
Hiroshige Mikamo
Publication date
01-12-2011
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 6/2011
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-011-0252-z

Other articles of this Issue 6/2011

Journal of Infection and Chemotherapy 6/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine